Search

Your search keyword '"Élez, E"' showing total 194 results

Search Constraints

Start Over You searched for: Author "Élez, E" Remove constraint Author: "Élez, E"
194 results on '"Élez, E"'

Search Results

1. Pembrolizumab versus chemotherapy in microsatellite instability-high or mismatch repair-deficient metastatic colorectal cancer: 5-year follow-up from the randomized phase III KEYNOTE-177 study

2. Maintenance with 5-FU/LV-aflibercept after induction with FOLFIRI-aflibercept versus FOLFIRI-aflibercept until progression as second-line treatment in older adults with metastatic colorectal cancer: the AFEMA phase II randomized trial

4. Immune checkpoint inhibitors for POLE or POLD1 proofreading-deficient metastatic colorectal cancer

5. Establishment of patient-derived tumor organoids to functionally inform treatment decisions in metastatic colorectal cancer

8. A signature of circulating microRNAs predicts the response to treatment with FOLFIRI plus aflibercept in metastatic colorectal cancer patients

12. Identifying and preventing burnout in young oncologists, an overwhelming challenge in the COVID-19 era: a study of the Spanish Society of Medical Oncology (SEOM)

18. Ultra-selection of metastatic colorectal cancer patients using next-generation sequencing to improve clinical efficacy of anti-EGFR therapy

24. Transition to the new EU CTIS Portal for Regulatory Clinical Trial Submissions: VHIO’s Start-Up Unit Analysis

28. Corrigendum to “Plasmatic BRAF-V600E allele fraction as a prognostic factor in metastatic colorectal cancer treated with BRAF combinatorial treatments”: [Annals of Oncology 34 (2023) 543-552]

30. 6P Circulating tumor DNA (ctDNA) next generation sequencing (NGS): Molecular prescreening for tailoring treatment in clinical trials

33. O-024 Circulating tumor DNA extended RAS mutational analysis as a surrogate of mutational status of tumor samples in metastatic colorectal cancer and its impact on patient selection for anti-EGFR therapy

34. LBA-3 Integrated analysis of cell-free DNA (cfDNA) BRAF mutant allele fraction (MAF) and whole exome sequencing in BRAFV600E metastatic colorectal cancer (mCRC) treated with BRAF-antiEGFR +/- MEK inhibitors

36. SO-32 Predictive impact of RNF43 mutation (mut) in pMMR/MSS BRAFV600E-mutated metastatic colorectal cancer (mCRC) patients (pts) treated with target therapy (TT) or chemotherapy (CT)

40. O-9 Health-related quality of life associated with trifluridine/tipiracil in combination with bevacizumab in refractory metastatic colorectal cancer: An analysis of the phase 3 SUNLIGHT trial

49. 4O VHIO immune gene expression profiling (VIGex) panel, a tool to explore tumor immune microenvironment

50. 3O VHIO immune gene-expression signature (VIGex) to enrich patient selection in immunotherapy phase I clinical trials

Catalog

Books, media, physical & digital resources